(Q37984565)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339439%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Biological agents for the treatment of uveitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339439%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339439%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Katrina A Mears

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339439%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Evan H Black

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339439%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

John J Huang

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339439%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

language of work or name

English

0 references

publication date

1 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339439%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

23 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339439%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339439%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339439%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

311-328

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339439%20AND%20SRC:MED&resulttype=core&format=json

Retrospective case review of pediatric patients with uveitis treated with infliximab

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Monoclonal antibodies against CD54 (ICAM-1) and CD11a (LFA-1) prevent and inhibit endotoxin-induced uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

The uveitogenic potential of retinal S-antigen in horses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Endogenous IRBP can be dispensable for generation of natural CD4+CD25+ regulatory T cells that protect from IRBP-induced retinal autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Factors associated with treatment response to etanercept in juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Anakinra treatment of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Interferon alpha-2a treatment for serpiginous choroiditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Interferon as a treatment for uveitis associated with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Interferon alpha (IFNalpha) and psychiatric syndromes: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Intravenous immunoglobulin therapy for resistant ocular Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Biologic therapies for inflammatory eye disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Anti-TNF-α Treatment: A Possible Promoter in Endogenous Uveitis? Observational Report on Six Patients: Occurrence of Uveitis Following Etanercept Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Contribution of TNF-α to Leukocyte Adhesion, Vascular Leakage, and Apoptotic Cell Death in Endotoxin-Induced Uveitis In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Efficacy of Etanercept in Preventing Relapse of Uveitis Controlled by Methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

The role of soluble TNF receptors for TNF-alpha in uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Anti-TNF-alpha therapy for sight threatening uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Biologics in the treatment of uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Biological response modifier therapy for refractory childhood uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Treatment of sarcoidosis with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Infliximab in the treatment of refractory posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Adalimumab in the therapy of uveitis in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Adalimumab for sight-threatening uveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Clinical experience with adalimumab in the treatment of ocular Behçet disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Adalimumab: a review of side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Daclizumab for treatment of birdshot chorioretinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Intravenous daclizumab for recalcitrant ocular inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Successful treatment of Wegener's granulomatosis associated scleritis with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Adhesion molecules in iris biopsy specimens from patients with uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Efalizumab: a review of events reported during clinical trials and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Campath-1H therapy in refractory ocular inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Complications and adverse reactions in the use of newer biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Monoclonal Antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) Inhibit Experimental Autoimmune Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Successful Treatment With Infliximab in a Patient With Diffuse Subretinal Fibrosis Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

Interferon-α2a and Vogt–Koyanagi–Harada disease: a double-edged sword?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.658366

10.1517/14712598.2012.658366

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339439%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference